Peptides Similar to AOD-9604
Compare AOD-9604 with related peptides and alternatives
📌TL;DR
- •6 similar peptides identified
- •Tesamorelin: Moderate - Both target fat metabolism through GH-related pathways
- •Semaglutide: Low-Moderate - Both studied for weight management, different mechanisms
Quick Comparison
| Peptide | Similarity | Key Differences |
|---|---|---|
| AOD-9604 (current) | - | - |
| Tesamorelin | Moderate - Both target fat metabolism through GH-related pathways | Tesamorelin is an FDA-approved GHRH analog that stimulates endogenous GH release, affecting the full spectrum of GH actions. AOD-9604 is an hGH fragment that acts independently of the GH receptor. |
| Semaglutide | Low-Moderate - Both studied for weight management, different mechanisms | Semaglutide is a GLP-1 receptor agonist with robust clinical evidence for weight loss (15-20% body weight). AOD-9604 targets lipolysis via beta-3 AR upregulation and failed to show significant weight loss in clinical trials. |
| CJC-1295 with DAC | Moderate - Both related to GH axis but through different mechanisms | CJC-1295 DAC is a long-acting GHRH analog that stimulates pituitary GH release and elevates IGF-1. AOD-9604 is an hGH fragment with no GH receptor interaction or IGF-1 effects. |
| CJC-1295 without DAC | Moderate - Both short-acting peptides in the GH/metabolic space | CJC-1295 without DAC stimulates pulsatile GH release through GHRH receptor activation. AOD-9604 does not stimulate GH release or act through the GH receptor. |
| Ipamorelin | Low-Moderate - Both used in metabolic research, entirely different mechanisms | Ipamorelin is a selective ghrelin receptor agonist that stimulates GH release from the pituitary. AOD-9604 does not interact with the ghrelin receptor or stimulate GH release. |
| Tirzepatide | Low - Both in metabolic/weight management space, vastly different evidence levels | Tirzepatide is a dual GIP/GLP-1 receptor agonist with the strongest clinical weight loss data of any pharmaceutical agent (up to 22.5% body weight loss). AOD-9604 failed its weight loss trial. |
TesamorelinModerate - Both target fat metabolism through GH-related pathways
Differences
Tesamorelin is an FDA-approved GHRH analog that stimulates endogenous GH release, affecting the full spectrum of GH actions. AOD-9604 is an hGH fragment that acts independently of the GH receptor.
Advantages
FDA-approved for HIV-associated lipodystrophy; proven efficacy for visceral fat reduction in clinical trials
Disadvantages
Elevates IGF-1 levels; full GH axis stimulation with broader systemic effects
SemaglutideLow-Moderate - Both studied for weight management, different mechanisms
Differences
Semaglutide is a GLP-1 receptor agonist with robust clinical evidence for weight loss (15-20% body weight). AOD-9604 targets lipolysis via beta-3 AR upregulation and failed to show significant weight loss in clinical trials.
Advantages
FDA-approved for obesity (Wegovy); vastly stronger clinical evidence; 15-20% weight loss in trials
Disadvantages
Different mechanism; significant GI side effects (nausea, vomiting); expensive
CJC-1295 with DACModerate - Both related to GH axis but through different mechanisms
Differences
CJC-1295 DAC is a long-acting GHRH analog that stimulates pituitary GH release and elevates IGF-1. AOD-9604 is an hGH fragment with no GH receptor interaction or IGF-1 effects.
Advantages
Sustained GH elevation; broader anabolic effects; longer half-life
Disadvantages
Elevates IGF-1; affects glucose metabolism; not GH-receptor-independent
CJC-1295 without DACModerate - Both short-acting peptides in the GH/metabolic space
Differences
CJC-1295 without DAC stimulates pulsatile GH release through GHRH receptor activation. AOD-9604 does not stimulate GH release or act through the GH receptor.
Advantages
Mimics natural pulsatile GH release; established synergy with GHRP peptides
Disadvantages
Requires multiple daily injections; elevates IGF-1; broader hormonal effects
IpamorelinLow-Moderate - Both used in metabolic research, entirely different mechanisms
Differences
Ipamorelin is a selective ghrelin receptor agonist that stimulates GH release from the pituitary. AOD-9604 does not interact with the ghrelin receptor or stimulate GH release.
Advantages
Highly selective GH stimulation with minimal cortisol or prolactin elevation
Disadvantages
Stimulates GH axis broadly; not specific to fat metabolism
TirzepatideLow - Both in metabolic/weight management space, vastly different evidence levels
Differences
Tirzepatide is a dual GIP/GLP-1 receptor agonist with the strongest clinical weight loss data of any pharmaceutical agent (up to 22.5% body weight loss). AOD-9604 failed its weight loss trial.
Advantages
FDA-approved; up to 22.5% weight loss in trials; dual receptor mechanism
Disadvantages
Different mechanism; significant GI side effects; requires prescription
Overview#
AOD-9604 occupies a unique position in the landscape of metabolic and weight-management peptides. As an hGH C-terminal fragment, it was designed to isolate the lipolytic properties of growth hormone from its growth-promoting effects. However, its clinical development for obesity was terminated after Phase IIb failure, placing it in a different evidence category from FDA-approved agents like semaglutide or tesamorelin.
When comparing AOD-9604 with similar peptides, the most important distinction is between peptides with proven clinical efficacy and regulatory approval versus those that remain investigational. AOD-9604 falls into the latter category for all indications, including both obesity and cartilage repair.
Comparison by Mechanism#
GH-Related Peptides#
AOD-9604 differs fundamentally from other GH-related peptides because it does not stimulate growth hormone release or interact with the growth hormone receptor:
| Feature | AOD-9604 | Tesamorelin | CJC-1295 DAC | CJC-1295 no DAC | Ipamorelin |
|---|---|---|---|---|---|
| Mechanism | Beta-3 AR upregulation | GHRH receptor agonist | GHRH receptor agonist | GHRH receptor agonist | Ghrelin receptor agonist |
| GH release | No | Yes | Yes | Yes | Yes |
| IGF-1 elevation | No | Yes | Yes | Yes | Yes |
| FDA approved | No | Yes (lipodystrophy) | No | No | No |
| Clinical trial weight loss | Failed Phase IIb | Proven for visceral fat | No obesity trials | No obesity trials | No obesity trials |
| Glucose effects | None observed | May worsen | May worsen | May worsen | Minimal |
The key advantage claimed for AOD-9604 is its metabolic selectivity: it is reported to promote fat metabolism without the IGF-1 elevation, glucose impairment, or growth-promoting effects of GH-axis peptides. However, this advantage is offset by the clinical failure to demonstrate meaningful weight loss in humans.
Weight Loss Peptides (GLP-1 Class)#
The GLP-1 receptor agonist class represents the current standard of care for pharmacological weight management and dramatically outperforms AOD-9604 in clinical evidence:
| Feature | AOD-9604 | Semaglutide (Wegovy) | Tirzepatide (Zepbound) | Liraglutide (Saxenda) |
|---|---|---|---|---|
| Mechanism | Beta-3 AR upregulation | GLP-1 receptor agonist | GIP/GLP-1 dual agonist | GLP-1 receptor agonist |
| Weight loss | Failed Phase IIb | ~15% body weight | Up to 22.5% body weight | ~8% body weight |
| FDA approved | No | Yes | Yes | Yes |
| Route | SC injection or oral | SC injection (weekly) | SC injection (weekly) | SC injection (daily) |
| GI side effects | Minimal | Significant (nausea, vomiting) | Significant | Significant |
| Cardiovascular benefit | Unknown | Demonstrated (SELECT trial) | Under investigation | Not demonstrated |
For weight management specifically, the evidence overwhelmingly favors GLP-1 receptor agonists over AOD-9604. The GLP-1 class has demonstrated robust, reproducible weight loss in large Phase 3 trials, while AOD-9604 failed its pivotal trial.
Comparison by Application#
Fat Metabolism Research#
For researchers studying fat metabolism mechanisms, AOD-9604 offers a unique tool as a GH fragment that promotes lipolysis through beta-3 AR upregulation without GH receptor activation. This specificity makes it useful for studying the isolated contribution of the hGH C-terminal domain to fat metabolism, independent of the broader GH signaling cascade.
In this research context, AOD-9604 has no direct equivalent, as it is the most extensively studied isolated lipolytic fragment of growth hormone.
Cartilage Repair Research#
AOD-9604 has been investigated for cartilage repair based on a single published rabbit study. In this application, the most relevant comparisons are with established cartilage-active peptides and treatments:
- Hyaluronic acid: Well-established viscosupplementation with extensive clinical data. AOD-9604 showed synergistic effects with HA in the rabbit model (PMID: 26275694).
- BPC-157: Another peptide studied for tissue repair, with a broader but primarily preclinical evidence base.
- Pentosan polysulfate: An established cartilage-active agent with clinical data in osteoarthritis.
For cartilage repair, AOD-9604 has weaker evidence than established therapies and should not be considered as a clinically validated alternative.
Growth Hormone Fragment Comparison#
AOD-9604 is sometimes compared with the closely related hGH Fragment 176-191 (the unmodified C-terminal fragment without the tyrosine substitution). The key differences are:
- AOD-9604 has the tyrosine substitution at the N-terminus (replacing the native phenylalanine) for improved stability
- AOD-9604 has a clinical development history with published human safety data
- hGH Fragment 176-191 has minimal independent published research
- The two peptides are sometimes conflated in non-scientific literature, but they are distinct compounds with different amino acid sequences
Summary#
AOD-9604's position among similar peptides is defined by two contrasting features: an extensive human safety database that exceeds most research peptides, and a clinical efficacy failure that places it below approved therapeutics. For researchers studying GH fragment biology and lipolytic mechanisms, AOD-9604 remains a valuable pharmacological tool. For individuals seeking weight management solutions, FDA-approved GLP-1 receptor agonists have vastly stronger evidence of efficacy.
Related Reading#
Frequently Asked Questions About AOD-9604
What are the main alternatives to AOD-9604?
The primary alternatives to AOD-9604 include Tesamorelin, Semaglutide, CJC-1295 with DAC, CJC-1295 without DAC, Ipamorelin, Tirzepatide. Each has a different mechanism of action and evidence profile. The choice between them depends on the specific research objectives.
How does AOD-9604 compare to Tesamorelin?
Moderate - Both target fat metabolism through GH-related pathways. Key differences: Tesamorelin is an FDA-approved GHRH analog that stimulates endogenous GH release, affecting the full spectrum of GH actions. AOD-9604 is an hGH fragment that acts independently of the GH receptor.. Advantages of Tesamorelin: FDA-approved for HIV-associated lipodystrophy; proven efficacy for visceral fat reduction in clinical trials. Disadvantages: Elevates IGF-1 levels; full GH axis stimulation with broader systemic effects.
How does AOD-9604 compare to Semaglutide?
Low-Moderate - Both studied for weight management, different mechanisms. Key differences: Semaglutide is a GLP-1 receptor agonist with robust clinical evidence for weight loss (15-20% body weight). AOD-9604 targets lipolysis via beta-3 AR upregulation and failed to show significant weight loss in clinical trials.. Advantages of Semaglutide: FDA-approved for obesity (Wegovy); vastly stronger clinical evidence; 15-20% weight loss in trials. Disadvantages: Different mechanism; significant GI side effects (nausea, vomiting); expensive.
Can AOD-9604 be combined with other peptides?
Some research protocols study AOD-9604 in combination with related peptides such as Tesamorelin, Semaglutide, CJC-1295 with DAC, CJC-1295 without DAC, Ipamorelin, Tirzepatide. However, combination studies are limited and no established guidelines exist for combining these peptides. Any combination use should be guided by available research data.
Explore Further
Disclaimer: For educational purposes only. Not medical advice. Read full disclaimer